In a transformative development for cancer care, pharmaceutical firms Merck and Moderna announced Wednesday that their personalized messenger RNA (mRNA)-based cancer therapy delivered promising positive results in a large-scale late-stage clinical trial, successfully reducing the recurrence of melanoma. The breakthrough finding has sent shockwaves through the global medical and financial communities, pushing Moderna’s share price up 145% to $154 and lifting Merck’s stock by more than 12% to $152.
The experimental treatment, named intismeran autogene, leverages the same foundational mRNA technology that powered the development of highly effective Covid-19 vaccines nearly a decade after the platform was first mainstreamed by the pandemic. While researchers have spent decades working to adapt mRNA technology for cancer treatment, this trial marks the first time an mRNA-based cancer drug has delivered positive outcomes in a large, phase-three level clinical study.
“Today marks an extraordinary milestone for Moderna, for mRNA science and, most importantly, for patients with cancer,” Moderna Chief Executive Stephane Bancel emphasized in an official statement.
The roughly one-year trial enrolled 1,137 participants who had undergone surgical removal of melanoma tumors. Patients were split randomly into two groups: two-thirds received the new personalized mRNA therapy in combination with pembrolizumab, the current gold-standard treatment for melanoma, while the remaining third received only pembrolizumab. The companies confirmed they will unveil full trial data at an upcoming international oncology conference and have already begun preparing regulatory submissions to seek formal approval for the treatment.
Independent oncology experts have welcomed the results as a watershed moment for cancer immunotherapy. Lennard Lee, an oncologist and assistant professor at the University of Oxford who was not involved in the trial, called the outcome “very encouraging” and noted that the full dataset is now eagerly anticipated by the global research community.
Marco Gerlinger, a professor of oncology at London’s Barts Cancer Institute, echoed the praise, pointing out that the results do more than benefit melanoma patients – they serve as long-awaited “proof of principle that personalised cancer vaccines work.” “I think it is fair to call it a breakthrough in the development of new cancer immunotherapies,” Gerlinger said, while adding that the initial press announcement lacked granular full-trial details that will be critical for further assessment.
Unlike traditional one-size-fits-all cancer treatments, the personalized mRNA therapy works by first collecting a tissue sample from a patient’s tumor, mapping its unique genetic mutational “fingerprint,” then designing a custom mRNA treatment targeted to that specific signature. Similar to Covid-19 mRNA vaccines, the treatment delivers synthetic molecular instructions wrapped in microscopic lipid bubbles that enter the body’s cells and trigger them to produce specific targets that train the immune system to recognize and attack cancer cells.
First conceptualized decades ago, mRNA technology rose to global prominence during the Covid-19 pandemic, when Moderna and Pfizer-BioNTech rolled out highly effective vaccines that dramatically reduced rates of severe illness and death from the virus. Since then, researchers have raced to adapt the platform to a wide range of other diseases, with cancer being the most high-priority area of research.
Melanoma is among the most aggressive forms of skin cancer, with more than 330,000 new cases diagnosed across the globe in 2022 alone. Looking ahead, Bancel confirmed that the two companies will continue expanding research into intismeran autogene, testing it in combination with pembrolizumab and other existing anti-cancer therapies, as well as a standalone treatment, across a wide range of tumor types and disease stages. Upcoming trials will explore the therapy’s effectiveness for lung, bladder, and kidney cancers in addition to melanoma, opening the door for a potential revolution in personalized cancer care.